Altium Capital Management LLC Takes $1.52 Million Position in ProQR Therapeutics (NASDAQ:PRQR)

Altium Capital Management LLC bought a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 575,000 shares of the biopharmaceutical company's stock, valued at approximately $1,524,000. Altium Capital Management LLC owned approximately 0.70% of ProQR Therapeutics as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in PRQR. BNP Paribas Financial Markets lifted its position in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 7,300 shares during the period. Invesco Ltd. bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at $32,000. Prudential Financial Inc. boosted its stake in shares of ProQR Therapeutics by 109.1% in the 4th quarter. Prudential Financial Inc. now owns 27,600 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 14,400 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth about $54,000. Finally, Ballentine Partners LLC acquired a new stake in shares of ProQR Therapeutics during the 4th quarter worth about $61,000. Institutional investors and hedge funds own 32.65% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Chardan Capital reaffirmed a "buy" rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday, March 14th. HC Wainwright raised their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, March 14th. Oppenheimer started coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an "outperform" rating and a $15.00 price objective on the stock. Finally, Citigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price for the company in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.50.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR traded up $0.08 on Wednesday, hitting $1.43. 377,435 shares of the stock were exchanged, compared to its average volume of 588,771. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.62. The stock has a market capitalization of $150.51 million, a price-to-earnings ratio of -4.47 and a beta of 0.25. The company's 50-day moving average price is $1.70 and its 200 day moving average price is $2.51.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).